In light of claims of improved efficacy and lower incidence of adverse effects compared with older drugs, second-generation antipsychotics have emerged as the predominant treatment for schizophrenia. A new meta-analysis concludes that the difference in efficacy between newer and older agents is small, and the current classification scheme for antipsychotics does not survive close scrutiny.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Leucht, S. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41 (2009).
Gründer, G., Hippius, H. & Carlsson, A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8, 197–202 (2009).
Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).
McEvoy, J. P. et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163, 600–610 (2006).
Leucht, S. et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166, 152–163 (2009).
Rosenheck, R. et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290, 2693–2702 (2003).
Jones, P. B. et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63, 1079–1087 (2006).
Carpenter, W. T. & Buchanan, R. W. Lessons to take home from CATIE. Psychiatr. Serv. 59, 523–525 (2008).
Ross, C. A., Margolis, R. L., Reading, S. A., Pletnikov, M. & Coyle, J. T. Neurobiology of schizophrenia. Neuron 52, 139–153 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. L. Margolis is a consultant for AstraZeneca.
Rights and permissions
About this article
Cite this article
Margolis, R. The choice of antipsychotics in schizophrenia. Nat Rev Neurol 5, 308–310 (2009). https://doi.org/10.1038/nrneurol.2009.68
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2009.68